<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592370</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-039</org_study_id>
    <nct_id>NCT01592370</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma</brief_title>
  <official_title>Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the side effects of treatment of the combination of
      nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NOTE: Currently, this study is only open to nivolumab+daratumumab vs daratumumab monotherapy
      in multiple myeloma patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2012</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 14, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab alone and in combination as measured by incidence of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities, and laboratory test abnormalities</measure>
    <time_frame>Up to 100 days after the last dose of study (expected to be no more than 225 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>7 time points up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration achieved at the end of dosing interval (trough concentration, all participants) [Cmin]</measure>
    <time_frame>7 time points up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>7 time points up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>7 time points up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)]</measure>
    <time_frame>7 time points up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration achieved at the end of study drug infusion (Ceoinf)</measure>
    <time_frame>7 time points up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Baseline (within 28 days of treatment), until disease progression in patients, up to week 156</time_frame>
    <description>BOR is defined as the best response designation over the study as a whole, recorded between the date of first dose and the last tumor assessment prior to subsequent therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Baseline up to week 156</time_frame>
    <description>ORR is defined as the proportion of patients whose BOR is either partial response (PR) or complete response (CR) divided by the number of treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response</measure>
    <time_frame>Baseline until disease progression in patients with multiple myeloma receiving nivolumab in combination with daratumumab, up to week 156</time_frame>
    <description>Duration of response is defined as the time when the measurement criteria are first met for objective response until the date of documented disease progression or death. For patients who neither progress nor die, the duration of response will be censored at the date of their last disease assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate (PFSR)</measure>
    <time_frame>Baseline up to week 156</time_frame>
    <description>Progression free survival (PFS) is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Severity Weighted Assessment Tool (mSWAT) for patients with cutaneous T cell lymphoma</measure>
    <time_frame>Baseline up to week 156</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as measured by the anti-drug antibody (ADA) status both at sample level and at patient level</measure>
    <time_frame>Baseline, 6 timepoints up to 120 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD) in patients with multiple myeloma receiving nivolumab in combination with daratumumab</measure>
    <time_frame>Up to 41 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 expression</measure>
    <time_frame>up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Nivolumab monotherapy (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab solution intravenously as specified
Enrollment is closed for this arm
Non-randomized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab and Ipilimumab solution intravenously as specified
Non-randomized
Enrollment is closed for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab + Lirilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-randomized
Enrollment is closed for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo + Dara + Pom + Dexa vs. Nivo + Dara</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized
Enrollment is closed this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab vs. Nivolumab + Daratumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Nivolumab monotherapy (Dose Escalation)</arm_group_label>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Nivolumab + Lirilumab</arm_group_label>
    <arm_group_label>Nivo + Dara + Pom + Dexa vs. Nivo + Dara</arm_group_label>
    <arm_group_label>Daratumumab vs. Nivolumab + Daratumumab</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
    <other_name>BMS-734016</other_name>
    <other_name>MDX010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lirilumab</intervention_name>
    <arm_group_label>Nivolumab + Lirilumab</arm_group_label>
    <other_name>BMS-986015</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <arm_group_label>Nivolumab + Lirilumab</arm_group_label>
    <arm_group_label>Nivo + Dara + Pom + Dexa vs. Nivo + Dara</arm_group_label>
    <arm_group_label>Daratumumab vs. Nivolumab + Daratumumab</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <arm_group_label>Nivo + Dara + Pom + Dexa vs. Nivo + Dara</arm_group_label>
    <other_name>Pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Nivo + Dara + Pom + Dexa vs. Nivo + Dara</arm_group_label>
    <other_name>Intensol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Have received at least 3 prior lines of therapy, including a proteasome inhibitor [PI]
             and an immunomodulatory agent [IMiD] OR have disease that is double refractory to a PI
             and IMiD

          -  More than 12 weeks post-transplant of your own blood forming stem cells (autologous
             transplant)

          -  Have detectable disease measured by a specific protein in your blood and/or urine

          -  Must consent to bone marrow aspirate or biopsy.

        Exclusion Criteria:

          -  Solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell
             dyscrasia, or monoclonal gammopathy of undetermined significance (MGUS), smoldering
             multiple myeloma (SMM), primary amyloidosis, Waldenstrom's macroglobulinemia, POEMS
             syndrome or active plasma cell leukemia

          -  Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti CTLA 4, or
             anti-CD38 antibody, or allogeneic stem cell transplantation

          -  Seropositive for human immunodeficiency virus (HIV), Hepatitis B surface antigen or
             Hepatitis C antibody positive (except if HCV-RNA negative), or history of active
             chronic hepatitis B or C

          -  History of central nervous system involvement or symptoms suggestive of central
             nervous system involvement by multiple myeloma

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Division Of Hematology &amp; Oncology Ctr. For Health Sciences</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomer Mark, Site 0017</last_name>
      <phone>720-848-1776</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University School Of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Of Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Alemany, Site 0023</last_name>
      <phone>407-303-5871</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0037</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin &amp; Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attaya Suvannasankha, Site 0019</last_name>
      <phone>317-278-5623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Al-Ola Abdallah, Site 0018</last_name>
      <phone>913-588-2545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Borrello, Site 003</last_name>
      <phone>410-614-0482</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Armand, Site 0015</last_name>
      <phone>617-667-3064</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Armand, Site 009</last_name>
      <phone>617-582-8437</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Ansell, Site 002</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0036</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Lesokhin, Site 001</last_name>
      <phone>646-888-3359</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0028</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0038</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OHSU Center for Hematologic Malignancies</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Scott, Site 006</last_name>
      <phone>503-494-4603</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0030</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0024</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute At The Univ. Of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Djordje Atanackovic, Site 005</last_name>
      <phone>801-213-4230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

